Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Syntis Bio Inc. is prosecuting patents in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating that the pending matters are being handled independently of one another. This separation suggests that the company is pursuing different technological sub-sectors or applications that fall under the jurisdiction of different administrative units. For a practitioner, this necessitates a strategy that accounts for the unique characteristics of 2 distinct art units.
The busiest examiner for the company is RONEY, CELESTE A, who has 1 pending office action. With a total of 2 pending office actions and 2 distinct examiners, the current prosecution workload is shared between different officials. Because the 2 pending office actions are being reviewed by 2 distinct examiners in 2 distinct art units, the company must manage separate sets of examiner expectations. This diversity in the prosecution landscape means that the outcome of 1 pending action may not necessarily predict the outcome of the other.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RONEY, CELESTE A | 1 | 62.8% | +17.5% |
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18363976 | ENGINEERED LEUCINE DECARBOXYLASES | YU, DAVID TUYANG | 43d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18418090 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | RONEY, CELESTE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18418090 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | RONEY, CELESTE A | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18418090 | PERMEATION ENHANCERS FOR GASTROINTESTINAL SYNTHETIC EPITHELIAL LININGS | RONEY, CELESTE A | 1612 | §103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18363976 | ENGINEERED LEUCINE DECARBOXYLASES | YU, DAVID TUYANG | 1635 | §112 | Non-Final OA | 43d | Pending | Aug 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial